A decade ago, after returning to finance from 30 years covering computer technology, I got into an argument over a company called Dendreon. You’ll see why this lingering thoughts connects me to BIIB stock below. Source: PictureDesignSwiss / Shutterstock.com Dendreon had launched a treatment for prostate cancer called Provenge. It is an immunotherapy, tied to
Stocks to sell
GameStop (NYSE:GME) stock has been one of 2021’s most incredible investing stories. The initial short squeeze was incredible to watch. Few market analysts could have ever imagined that a struggling mall retailer like GameStop could see its shares surge thousands of percent. Source: rblfmr / Shutterstock.com That surge, in turn, saved the company. GameStop raised
It’s been a wild month for investors in the company formerly known as Torchlight Energy. Torchlight traded as TRCH stock and sought to develop its Hazel property into a major oil play. Source: FreezeFrames / Shutterstock.com However, Hazel didn’t end up striking it rich, and Torchlight looked to exit the oil and gas business. Instead,
Torchlight Energy Resources and TRCH stock are now history. How so? Well, the company recently merged with Metamaterials to form the new Meta Materials (NASDAQ:MMAT) stock. Source: Shutterstock However, it’s not as simple as that. Rather, TRCH stock has made a lot of news lately and moved way too fast. Further, the mix of news
A deep dive into SoFi Technologies (NASDAQ:SOFI) stock provides reason enough not to get on board. Those fundamentals will provide the backbone of my argument against investing in SoFi. Source: rafapress / Shutterstock.com I would argue that potential investors avoid the buzz and buzzwords around the SPAC gone public financial services company. Specifically, I’d urge investors,
I’m not breaking news to say that the U.S. real estate market is on fire. This has helped place many homebuilders in the spotlight as investments to consider. But one thing you want to understand is, it’s not just individuals and families that are buying houses these days. There are hedge funds, alternative investment funds
As traders look desperately for another short squeeze candidate, some folks have turned their attention to Creatd (NASDAQ:CRTD). However, a closer look could suggest a bleak future for anyone holding CRTD stock, which I give a “D” in my Portfolio Grader. Source: Shutterstock First of all, trying to predict the next short squeeze stock is a
The stock market has gotten volatile lately. Shares dropped sharply in recent days on worries around the renewed spread of Covid-19 and its Delta variant. However, stocks rapidly rebounded as investors went bargain-hunting, particularly in Covid-impacted stocks. In any case, the stock market indexes remain fairly near their all-time highs. This makes it a good
When it comes to stocks, I tend to be a glass-half-full kind of person, which is why I don’t often write about stocks to sell. Alas, you can run, but you can’t hide. So I’ve been asked to come up with 10 names I feel investors ought to jettison before they crash and burn. What
Based on my financial analysis, I would not touch Bionano Genomics (NASDAQ:BNGO) right now. I would run fast and far away from BNGO stock. But why? There are several reasons, and they all have to do with fundamentals. Source: Natali_ Mis/ShutterStock.com While the company has a positive catalyst here and there, its revenue and subsequent
Health insurance company Clover Health (NASDAQ:CLOV) is on a mission to lower costs for Medicare patients. So far, it is spending more money than it brings in. Additionally, activist short-seller Hindenburg Research released a scathing report that criticizes its business model and the quality of its software. As a result, CLOV stock is incredibly volatile
Many may be waiting for the other shoe to drop with Gamestop (NYSE:GME) stock. But not even market-wide jitters about the Delta variant could knock down the most popular “meme stock.” In fact, on the day the Dow slumped over concerns, GME stock ticked higher rather than lower. Source: Emil O / Shutterstock.com Will this
AMC (NYSE:AMC) announced the appointment of CEO Adam Aron to the additional position of Chairman of the Board on July 21. Before you run out to buy AMC stock on the news, you might want to do a stress test on America’s largest movie theater chain. Source: Sundry Photography / Shutterstock.com You might not like
In the rosiest of scenarios for Ocugen (NASDAQ:OCGN) stock, the Covaxin vaccine for the novel coronavirus will be approved by the FDA only around the second quarter of 2023. And the company appears to be dragging its feet on getting the process started. Source: shutterstock.com/PhotobyTawat Meanwhile, information I recently uncovered suggests that Canada will probably
Is healthcare insurer Clover Health Investments (NASDAQ:CLOV) stock more than a meme play? Source: Valeri Potapova / Shutterstock.com This is the fundamental question that both professional and retail investors are trying to answer after CLOV stock was targeted in late May by the meme stock crowd that congregates on the WallStreetBets Reddit forum. The share
When I last wrote about Fisker (NYSE:FSR) stock in April, I said I liked the stock better when it was trading near $13 a share. Source: T. Schneider / Shutterstock.com It seems at least some investors agreed that they preferred an even lower entry point. FSR stock dropped below the $10 mark in late May. But
AMC Entertainment (NYSE:AMC) stock, even with its recent troubles, is still up approximately 1,500% year-to-date. Source: Sundry Photography / Shutterstock.com When meme stock mania kicked off in January, many Wall Street analysts expected it to blow over quickly, but it hasn’t. Indeed, leading meme names such as GameStop (NYSE:GME) and AMC remain at sharply higher
Clover Health Investments (NASDAQ:CLOV) recently reported Q1 revenue and earnings on May 17. The numbers weren’t particularly thrilling for CLOV stockholders. Source: Valeri Potapova / Shutterstock.com On May 13 I wrote that the Medicare Advantage insurer would likely report 21% higher revenue year-over-year. But I also cautioned that CLOV stock was unlikely to move much
In any other circumstance, Opendoor Technologies (NASDAQ:OPEN) stock may have been a no-brainer investment. Source: PREMIO STOCK/Shutterstock.com As you probably know, owning real estate is the epitome of the American Dream — but the paperwork to seal the deal is a veritable nightmare. Opendoor’s digitalization of the buying and selling process is the answer we’ve
Small biotech companies such as Denmark’s Orphazyme (NASDAQ:ORPH) usually have one major product, which pushes them into the spotlight. For ORPH stock, that one product is Arimoclomol. Source: Iryna Imago / Shutterstock.com Arimoclomol is a drug that could treat the rare progressive genetic disorder called Niemann-Pick Disease Type C (NPC). Investors looking for a breakthrough